



US011066458B2

(12) **United States Patent**
Furfine et al.(10) **Patent No.:** **US 11,066,458 B2**(45) **Date of Patent:** ***Jul. 20, 2021**(54) **VEGF ANTAGONIST FORMULATIONS
SUITABLE FOR INTRAVITREAL
ADMINISTRATION***A61K 47/02* (2006.01)*A61K 47/10* (2017.01)(52) **U.S. Cl.**CPC *C07K 14/71* (2013.01); *A61K 9/0019*
(2013.01); *A61K 9/0048* (2013.01); *A61K 9/19*
(2013.01); *A61K 38/179* (2013.01); *A61K*
38/1793 (2013.01); *A61K 47/02* (2013.01);
A61K 47/10 (2013.01); *A61K 47/26* (2013.01);
A61M 5/178 (2013.01); *C07K 14/47*
(2013.01); *C07K 14/4705* (2013.01); *C07K*
2319/00 (2013.01); *C07K 2319/30* (2013.01)(71) Applicant: **REGENERON
PHARMACEUTICALS, INC.,**
Tarrytown, NY (US)(72) Inventors: **Eric Furfine**, Concord, MA (US);
Daniel Dix, LaGrangeville, NY (US);
Kenneth Graham, Pleasant Valley, NY
(US); **Kelly Frye**, Mendham, NJ (US)(73) Assignee: **REGENERON
PHARMACEUTICALS, INC.,**
Tarrytown, NY (US)(58) **Field of Classification Search**

None

See application file for complete search history.

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 42 days.This patent is subject to a terminal dis-
claimer.(21) Appl. No.: **16/582,486**(22) Filed: **Sep. 25, 2019**(65) **Prior Publication Data**

US 2020/0017572 A1 Jan. 16, 2020

Related U.S. Application Data(60) Continuation of application No. 16/159,269, filed on
Oct. 12, 2018, now Pat. No. 10,464,992, which is a
continuation of application No. 15/879,294, filed on
Jan. 24, 2018, now Pat. No. 10,400,025, which is a
continuation of application No. 15/095,606, filed on
Apr. 11, 2016, now Pat. No. 9,914,763, which is a
continuation of application No. 14/330,096, filed on
Jul. 14, 2014, now Pat. No. 9,340,594, which is a
continuation of application No. 13/914,996, filed on
Jun. 11, 2013, now Pat. No. 8,802,107, which is a
continuation of application No. 13/329,770, filed on
Dec. 19, 2011, now Pat. No. 8,481,046, which is a
continuation of application No. 12/833,417, filed on
Jul. 9, 2010, now Pat. No. 8,092,803, which is a
continuation of application No. 12/560,885, filed on
Sep. 16, 2009, now Pat. No. 7,807,164, which is a
division of application No. 11/818,463, filed on Jun.
14, 2007, now Pat. No. 7,608,261.(60) Provisional application No. 60/814,484, filed on Jun.
16, 2006.(51) **Int. Cl.***A61K 38/18* (2006.01)*C07K 14/71* (2006.01)*C07K 19/00* (2006.01)*A61K 9/00* (2006.01)*A61K 9/19* (2006.01)*A61K 38/17* (2006.01)*C07K 14/47* (2006.01)*A61M 5/178* (2006.01)*A61K 47/26* (2006.01)(56) **References Cited****U.S. PATENT DOCUMENTS**6,100,071 A 8/2000 Davis-Smyth et al.
6,171,586 B1 1/2001 Lam et al.
6,897,294 B2 5/2005 Davis-Smyth et al.
7,052,691 B2 5/2006 Sleeman et al.
7,608,261 B2 † 10/2009 Furfine
8,110,546 B2 2/2012 Dix et al.
9,340,594 B2 † 5/2016 Furfine
9,580,489 B2 † 2/2017 Furfine
10,464,992 B2 11/2019 Furfine et al.
2003/0113316 A1 6/2003 Kaisheva et al.
(Continued)**FOREIGN PATENT DOCUMENTS**JP 10273450 10/1998
JP H11510170 9/1999
(Continued)**OTHER PUBLICATIONS**Fraser, Hamis M., et al., "Single Injections of Vascular Endothelial
Growth Factor Trap Block Ovulation in the Macaque and Produced
Prolonged, Dose-Related Suppression of Ovarian Function," (2004)
J. Clin. Endocrin. & Metabol. 90(2):1114-1122.

(Continued)

Primary Examiner — Christine J Saoud*Assistant Examiner* — Jon M Lockard(74) *Attorney, Agent, or Firm* — Karl Bozicevic;
Bozicevic, Field & Francis LLP(57) **ABSTRACT**Ophthalmic formulations of a vascular endothelial growth
factor (VEGF)-specific fusion protein antagonist are pro-
vided suitable for intravitreal administration to the eye. The
ophthalmic formulations include a stable liquid formulation
and a lyophilizable formulation. Preferably, the protein
antagonist has an amino acid sequence of SEQ ID NO:4.**66 Claims, No Drawings****Specification includes a Sequence Listing.**

(56)

References Cited**U.S. PATENT DOCUMENTS**

2003/0138417	A1	7/2003	Kaisheva et al.
2004/0197324	A1	10/2004	Liu et al.
2005/0281831	A1	12/2005	Davis-Smyth et al.
2006/0217311	A1	9/2006	Dix et al.
2008/0085276	A1	4/2008	Wiegand et al.
2014/0012227	A1	1/2014	Sigg et al.

FOREIGN PATENT DOCUMENTS

JP	2002516871	6/2002
WO	WO 97/04801	2/1997
WO	WO1998045331	† 10/1998
WO	WO 99/62536	12/1999
WO	WO2000075319	† 12/2000
WO	WO 2004/091658	10/2004
WO	WO 2005/000895	1/2005
WO	WO 2005/011734	2/2005
WO	WO 2005/020972	3/2005
WO	WO 2006/047325	5/2006
WO	WO 2006/088650	8/2006
WO	WO 2006/104852	10/2006

OTHER PUBLICATIONS

Anonymous: "Lucentis in the treatment of neovascular (wet) age-related macular degeneration (AMD)", Jan. 1, 2007, pp. 1-54.

Petition for Inter Partes Review of U.S. Pat. No. 10,464,992, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 59 pgs.

File History of U.S. Pat. No. 10,464,992, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 124 pgs.

Declaration of Dr. Reiner Gentz, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 76 pgs.

Fraser et al., "Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produce a Prolonged, Dose-Related Suppression of Ovarian Function," *J. Clin. Endocrinol. & Metab.*, 90(2):1114-1122 (2004).

Wulff et al., "Prevention of Thecal Angiogenesis, Antral Follicular Growth, and Ovulation in the Primate by Treatment with Vascular Endothelial Growth Factor Trap R1R2," *Endocrinology*, 143(7):2797-2807 (2002).

Certificate of Correction dated Mar. 3, 2020, in U.S. Pat. No. 10,464,992, 1 pg.

Holash et al., "VEGF-Trap: A VEGF blocker with potent antitumor effects," *PNAS*, 99(17):11393-11398 (2002).

Response to Office Action in U.S. Appl. No. 12/835,065, filed Nov. 22, 2011, as submitted to the USPTO dated Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 4 pgs.

Declaration Pursuant to 37 C.F.R. § 1.131 of Daniel B. Dix, Kelly Frye, and Susan Kautz in Support of Response to Office Action in U.S. Appl. No. 12/835,065, filed Nov. 22, 2011, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 11 pgs.

Resume of Reiner Gentz, Ph.D., as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 3 pgs.

Rudge et al., "VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene®-based Discovery of the Next Generation of Angiogenesis Targets," *Cold Spring Harbor Symposia on Quantitative Biology*, 70:411-418 (2004).

Chi et al., "Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation," *Pharmaceutical Research*, 20(9):1325-1336 (2003).

Bontempo, "Preformulation Development of Parenteral Biopharmaceuticals," *Drugs and the Pharmaceutical Sciences*, 85:91-108 (1997).

"Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products," U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 25 pgs.

Parkins et al., "The formulation of biopharmaceutical products," *Pharmaceutical Science & Technology Today*, 3(4):129-137 (2000). Randolph et al., "Surfactant-Protein Interactions," *Rational Design of Stable Protein Formulations*, pp. 159-175, Springer, Boston, MA (2002).

"Phosphate buffer," Cold Spring Harbor Protocols, 2006:pdb.rec8543, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 1 pg.

LUCENTIS® label, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 14 pgs.

AVASTIN® label, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 37 pgs.

REMICADE® label, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 58 pgs.

XOLAIR® label, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 17 pgs.

RAPTIVA® label, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 36 pgs.

SIMULECT® label, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 7 pgs.

HERCEPTIN® label, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 2 pgs.

Andersen et al., "Recombinant protein expression for therapeutic applications," *Current Opinion in Biotechnology*, 13:117-123 (2002).

Janeway et al., "The structure of a typical antibody molecule," *Immunobiology: The Immune System in Health and Disease*, 5th edition, New York: Garland Science, 6 pgs. (2001).

Drug Vehicle (Code C927), National Cancer Institute (NCI), retrieved Jan. 6, 2021, from <https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C927>, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 2 pgs.

Controls in SCI experiments, RegenBase, retrieved Jan. 6, 2021, from <<http://regenbase.org/control-groups.html>>, as submitted to the USPTO on Jan. 7, 2021, in Inter Partes Review No. IPR2021-00402, 2 pgs.

USPTO Communication on Ex Parte Reexamination of U.S. Appl. No. 10/464,992, pp. 1-12, published Apr. 1, 2020, USPTO.†

Ex Parte Request for Reexamination of U.S. Appl. No. 10/464,992, pp. 1-70, published Feb. 11, 2020, USPTO.†

† cited by third party

1

VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. patent application Ser. No. 14/330,096, filed Jul. 14, 2014, which is a continuation of U.S. patent application Ser. No. 13/914,996, filed Jun. 11, 2013, which issued as U.S. Pat. No. 8,802,107 on Aug. 12, 2014, which is a continuation application of U.S. patent application Ser. No. 13/329,770, filed Dec. 19, 2011, which issued as U.S. Pat. No. 8,481,046 on Jul. 9, 2013, which is a continuation application of U.S. patent application Ser. No. 12/833,417, filed Jul. 9, 2010, which issued as U.S. Pat. No. 8,092,803 on Jan. 10, 2012, which is a continuation application of U.S. patent application Ser. No. 12/560,885, filed Sep. 16, 2009, which issued as U.S. Pat. No. 7,807,164 on Oct. 5, 2010, which is a divisional application of U.S. patent application Ser. No. 11/818,463, filed Jun. 14, 2007, which issued as U.S. Pat. No. 7,608,261 on Oct. 27, 2009, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/814,484, filed 16 Jun. 2006, which applications are each hereby incorporated by reference.

BACKGROUND OF INVENTION

Field of the Invention

The present invention is directed to pharmaceutical formulations suitable for intravitreal administration comprising agents capable of inhibiting vascular endothelial growth factor (VEGF), and to methods for making and using such formulations. The invention includes liquid pharmaceutical formulations having increased stability, as well as formulations that may be lyophilize and reconstituted for intravitreal administration.

Statement of Related Art

Vascular endothelial growth factor (VEGF) expression is nearly ubiquitous in human cancer, consistent with its role as a key mediator of tumor neoangiogenesis. Blockade of VEGF function, by binding to the molecule or its VEGFR-2 receptor, inhibits growth of implanted tumor cells in multiple different xenograft models (see, for example, Gerber et al. (2000) *Cancer Res.* 60:6253-6258). A soluble VEGF-specific fusion protein antagonist, termed a "VEGF trap" has been described (Kim et al. (2002) *Proc. Natl. Acad. Sci. USA* 99:11399-404; Holash et al. (2002) *Proc. Natl. Acad. Sci. USA* 99:11393-8), which applications are specifically incorporated by reference in their entirety.

Ophthalmic formulations are known, see for example, U.S. Pat. Nos. 7,033,604 and 6,777,429. An ophthalmic formulation of a VEGF antibody is described in U.S. Pat. No. 6,676,941.

Lyophilization (freeze drying under controlled conditions) is commonly used for long-term storage of proteins. The lyophilized protein is substantially resistant to degradation, aggregation, oxidation, and other degenerative processes while in the freeze-dried state (see, for example, U.S. Pat. No. 6,436,897).

BRIEF SUMMARY OF THE INVENTION

Stable formulations of a VEGF-specific fusion protein antagonist are provided. Pharmaceutically acceptable for-

2

mulations are provided that comprise a VEGF "trap" antagonist with a pharmaceutically acceptable carrier. In specific embodiments, liquid and lyophilized formulations are provided.

5 In a first aspect, a stable liquid ophthalmic formulation of a VEGF-specific fusion protein antagonist is provided, comprising a fusion protein that comprises a receptor component consisting essentially of an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component (also termed a "VEGF trap"). In a specific embodiment of the VEGF-specific fusion protein antagonist, the first VEGF receptor is Flt1 and the second VEGF receptor is Flk1 or Flt4. In a more specific embodiment the fusion protein has the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. Preferably, the VEGF antagonist is a dimer comprising two fusion proteins of SEQ ID NO:4.

In one aspect, a stable liquid ophthalmic formulation is provided that comprises 1-100 mg/ml VEGF-specific fusion protein antagonist, 0.01-5% of one or more organic solvent(s), 30-150 mM of one or more tonicity agent(s), 5-40 mM of a buffering agent, and optionally, 1.0-7.5% of a stabilizing agent, pH between about 5.8-7.0.

25 In one or more specific embodiments, the organic co-solvent may be polysorbate, for example, polysorbate 20 or polysorbate 80, polyethylene glycol (PEG), for example, PEG 3350, or propylene glycol, or a combination thereof; the tonicity agent may be, for example, sodium chloride or potassium chloride; the stabilizing agent may be sucrose, sorbitol, glycerol, trehalose, or mannitol; and the buffering agent may be, for example, phosphate buffer. In a specific embodiment, the phosphate buffer is a sodium phosphate buffer.

35 In various embodiments, the organic co-solvent is polysorbate and/or PEG, the stabilizing agent is sucrose, the buffering agent is phosphate buffer, and the tonicity agent is sodium chloride.

More specifically, the stable liquid ophthalmic formulation comprises about 40-50 mg/ml of the VEGF antagonist (SEQ ID NO:4), about 10 mM phosphate buffer, 0.01-3% polysorbate and/or PEG, 40-135 mM sodium chloride, and optionally 5.0% sucrose, pH about 6.2-6.3.

45 In a specific preferred embodiment, the stable liquid ophthalmic formulation comprises about 50 mg/ml of the VEGF antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer, 50 mM sodium chloride, 0.1% polysorbate, and 5% sucrose, pH about 6.2-6.3.

In a specific preferred embodiment, the stable liquid ophthalmic formulation comprises about 50 mg/ml of the VEGF antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer, 50 mM sodium chloride, 3% PEG, and 5% sucrose, pH about 6.2-6.3.

55 In a specific preferred embodiment, the stable liquid ophthalmic formulation comprises about 40 mg/ml of the VEGF antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer, 40 mM sodium chloride, 0.03% polysorbate, and 5% sucrose, pH about 6.2-6.3.

60 In a specific preferred embodiment, the stable liquid ophthalmic formulation comprises about 40 mg/ml of the VEGF antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer, 135 mM sodium chloride, and 0.03% polysorbate, pH about 6.2-6.3.

In another aspect, a stable liquid ophthalmic formulation is provided that comprises 1-100 mg/ml VEGF-specific fusion protein antagonist; 0.01-5% of one or more organic co-solvent(s); 5-40 mM of a buffering agent; and optionally

3

30-150 mM of one or more tonicity agent(s) and/or 1.0-7.5% of a stabilizing agent; having a pH between about 5.8-7.0.

In various embodiments, the VEGF antagonist (SEQ ID NO:4) is present at a concentration of about 10 to about 80 mg/ml. In various embodiments, the VEGF antagonist (SEQ ID NO:4) is present at a concentration of about 10, about 20, about 30, about 40, about 50, about 60, about 70, or about 80 mg/ml. In a preferred embodiment, the VEGF antagonist (SEQ ID NO:4) is present at a concentration of about 40 mg/ml.

In another embodiment, the stabilizing agent is selected from one or more of sucrose, sorbitol, glycerol, trehalose, and mannitol.

In another embodiment, the organic co-solvent is selected from one or more of polysorbate, for example, polysorbate 20 or polysorbate 80, polyethylene glycol (PEG), for example, PEG 3350, and propylene glycol.

In another embodiment, the buffer is a phosphate buffer, for example, sodium phosphate.

In another embodiment, the tonicity agent is a salt, for example, sodium chloride.

In one embodiment, the stable liquid ophthalmic formulation comprises 10 mM sodium phosphate buffer, about 0.03 to about 0.1% polysorbate and/or about 3% PEG or propylene glycol, about 40 mM sodium chloride, and about 5% sucrose. In a specific embodiment, the stable liquid ophthalmic formulation comprises 10 mM sodium phosphate buffer, about 0.03% polysorbate, about 40 mM sodium chloride, and about 5% sucrose. In another specific embodiment, the pH of the formulation is about 6.2 to about 6.3. In another specific embodiment, the pH is achieved by mixing mono- and dibasic sodium phosphate to the desired pH without acid/base titration.

In a specific embodiment, the stable liquid ophthalmic formulation consists essentially of a VEGF antagonist (SEQ ID NO:4) at 40 mg/ml, 10 mM sodium phosphate buffer, polysorbate at 0.03%, sodium chloride at 40 mM, and sucrose at 5%, pH 6.2-6.3.

In another aspect, a stable liquid ophthalmic formulation is provided that comprises about 10 to about 80 mg/ml VEGF antagonist, about 10 mM sodium phosphate buffer, about 0.03% polysorbate, and about 135 mM sodium chloride, pH 6.2 to 6.3.

In various embodiments, the VEGF antagonist (SEQ ID NO:4) is present at a concentration of about 10 to about 80 mg/ml. In various embodiments, the VEGF antagonist (SEQ ID NO:4) is present at a concentration of about 10, about 20, about 30, about 40, about 50, about 60, about 70, or about 80 mg/ml. In a specific embodiment, the VEGF antagonist (SEQ ID NO:4) is present at a concentration of about 40 mg/ml.

In one embodiment, the stable liquid ophthalmic formulation comprises 40 mg/ml of VEGF antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer, 0.03% polysorbate, and 135 mM sodium chloride at pH 6.2-6.3. In a specific embodiment, the stable liquid ophthalmic formulation consists essentially of 40 mg/ml of VEGF antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer, 0.03% polysorbate, and 135 mM sodium chloride at pH 6.2-6.3.

In another aspect, a lyophilizable formulation of a VEGF antagonist is provided, wherein upon lyophilization followed by reconstitution, a stable liquid ophthalmic formulation as described herein is obtained.

In another aspect, a lyophilizable formulation of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist is provided, comprising 5-50 mg/ml of the VEGF antagonist, 5-25 mM buffer, such as phosphate buffer,

4

0.01 to 0.15% of one or more of an organic co-solvent, such as polysorbate, propylene glycol and/or PEG, and optionally 1-10% of a stabilizing agent such as sucrose, sorbitol, trehalose, glycerol, or mannitol, pH about 5.8-7.0. In various embodiments, the VEGF antagonist (SEQ ID NO:4) is present at about 5, about 10, about 20, about 30, or about 40 mg/ml. In a specific embodiment, the lyophilizable ophthalmic formulation of the invention comprises 20 mg/ml of the VEGF antagonist, 10 mM sodium phosphate buffer, 0.03% polysorbate, 0.1% PEG, and 2.5% sucrose, pH about 6.2-6.3. In further embodiments, the lyophilizable formulation further comprises sodium chloride. In a specific embodiment, the sodium chloride is present at a concentration of about 20 mM. In another specific embodiment, the sodium chloride is present at a concentration of about 67.5 mM.

In another specific embodiment, the lyophilizable ophthalmic formulation of the invention comprises 20 mg/ml of the VEGF antagonist, 5 mM sodium phosphate buffer, 0.015% polysorbate, 20 mM sodium chloride, and 2.5% sucrose, pH about 6.2-6.3.

In another embodiment, the lyophilizable ophthalmic formulation comprises 5 mg/ml, 10 mg/ml, or 40 mg/ml VEGF antagonist, 5 mM sodium phosphate buffer, 0.015% polysorbate, 20 mM sodium chloride, and 2.5% sucrose, at pH 6.2-6.3. In a specific embodiment, the lyophilizable ophthalmic formulation consists essentially of 5 mg/ml, 10 mg/ml, or 40 mg/ml VEGF antagonist (SEQ ID NO:4), 5 mM sodium phosphate buffer, 0.015% polysorbate, 20 mM sodium chloride, and 2.5% sucrose, at pH 6.2-6.3.

In another specific embodiment, the lyophilizable ophthalmic formulation comprises 20 mg/ml of the VEGF antagonist, 5 mM sodium phosphate buffer, 0.015% polysorbate, and 67.5 mM sodium chloride, pH about 6.2-6.3. In a more specific embodiment, the lyophilizable ophthalmic formulation consists essentially of 20 mg/ml of the VEGF antagonist (SEQ ID NO:4), 5 mM sodium phosphate buffer, 0.015% polysorbate, and 67.5 mM sodium chloride, pH 6.2-6.3.

In another specific embodiment, the lyophilizable ophthalmic formulation comprises 5 mg/ml, 10 mg/ml, or 40 mg/ml VEGF antagonist, 5 mM sodium phosphate buffer, 0.015% polysorbate, and 67.5 mM sodium chloride, pH about 6.2-6.3. In a more specific embodiment, the lyophilizable ophthalmic formulation consists essentially of 5 mg/ml, 10 mg/ml, or 40 mg/ml VEGF antagonist (SEQ ID NO:4), 5 mM sodium phosphate buffer, 0.015% polysorbate, and 67.5 mM sodium chloride, pH about 6.2-6.3.

Generally, the reconstituted formulation is about 2 times the concentration of the pre-lyophilized formulation, e.g., a 20 mg fusion protein/ml pre-lyophilized formulation is reconstituted to a final formulation of 40 mg fusion protein/ml.

Generally, the lyophilized formulation is reconstituted with sterile water suitable for injection. In one embodiment, the reconstitution liquid is bacteriostatic water.

In another aspect, the invention features a method of producing a lyophilized formulation of a VEGF-specific fusion protein antagonist, comprising subjecting the lyophilizable formulation of the invention to lyophilization to generate a lyophilized formulation. The lyophilized formulation may be lyophilized by any method known in the art for lyophilizing a liquid.

In another related aspect, the invention features a method of producing a reconstituted lyophilized formulation of a VEGF antagonist, comprising reconstituting the lyophilized formulation of the invention to a reconstituted formulation. In one embodiment, the reconstituted formulation is twice

5

the concentration of the pre-lyophilized formulation, e.g., the method of the invention comprises: (a) producing a pre-lyophilized formulation of a VEGF-specific fusion protein antagonist, (b) subjecting the pre-lyophilized formulation of step (a) to lyophilization; and (c) reconstituting the lyophilized formulation of step (b).

The invention further features ophthalmic formulations provided in a pre-filled syringe or vial, particularly suitable for intravitreal administration.

Other objects and advantages will become apparent from a review of the ensuing detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is not limited to particular methods, and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting unless indicated, since the scope of the present invention will be limited only by the appended claims.

Unless stated otherwise, all technical and scientific terms and phrases used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference.

General Description

Safe handling and administration of formulations comprising proteins represent significant challenges to pharmaceutical formulators. Proteins possess unique chemical and physical properties that present stability problems: a variety of degradation pathways exist for proteins, implicating both chemical and physical instability. Chemical instability includes deamination, aggregation, clipping of the peptide backbone, and oxidation of methionine residues. Physical instability encompasses many phenomena, including, for example, aggregation and/or precipitation.

Chemical and physical stability can be promoted by removing water from the protein. Lyophilization (freeze-drying under controlled conditions) is commonly used for long-term storage of proteins. The lyophilized protein is substantially resistant to degradation, aggregation, oxidation, and other degenerative processes while in the freeze-dried state. The lyophilized protein may be reconstituted with water optionally containing a bacteriostatic preservative (e.g., benzyl alcohol) prior to administration.

Definitions

The term "carrier" includes a diluent, adjuvant, excipient, or vehicle with which a composition is administered. Carriers can include sterile liquids, such as, for example, water and oils, including oils of petroleum, animal, vegetable or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil and the like.

The term "excipient" includes a non-therapeutic agent added to a pharmaceutical composition to provide a desired consistency or stabilizing effect. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium

6

stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.

The term "lyophilized" or "freeze-dried" includes a state of a substance that has been subjected to a drying procedure such as lyophilization, where at least 90% of moisture has been removed.

VEGF Antagonists

A VEGF antagonist is a compound capable of blocking or inhibiting the biological action of vascular endothelial growth factor (VEGF), and includes fusion proteins capable of trapping VEGF. In a preferred embodiment, the VEGF antagonist is the fusion protein of SEQ ID NO:2 or 4; more preferably, SEQ ID NO:4. In specific embodiments, the VEGF antagonist is expressed in a mammalian cell line such as a CHO cell and may be modified post-translationally. In a specific embodiment, the fusion protein comprises amino acids 27-457 of SEQ ID NO:4 and is glycosylated at Asn residues 62, 94, 149, 222 and 308. Preferably, the VEGF antagonist is a dimer composed of two fusion proteins of SEQ ID NO:4.

The VEGF antagonist of the methods and formulations of the invention can be prepared by any suitable method known in the art, or that comes to be known. The VEGF antagonist is preferably substantially free of protein contaminants at the time it is used to prepare the pharmaceutically acceptable formulation. By "substantially free of protein contaminants" is meant, preferably, that at least 90% of the weight of protein of the VEGF-specific fusion protein antagonist preparation used for making a formulation is VEGF fusion protein antagonist protein, more preferably at least 95%, most preferably at least 99%. The fusion protein is preferably substantially free of aggregates. "Substantially free of aggregates" means that at least 90% of the weight of fusion protein is not present in an aggregate at the time the fusion protein is used to prepare the pharmaceutically effective formulation. Unless stated otherwise, the phosphates employed are sodium phosphates and a desired buffering pH is achieved by mixing appropriate amounts of mono- and dibasic sodium phosphate.

Stable Liquid Ophthalmic Formulations

In one aspect, the invention provides a stable pharmaceutically acceptable formulation comprising a VEGF antagonist, wherein the formulation is a liquid formulation suitable for ophthalmic use. Preferably, the liquid formulation comprises a pharmaceutically effective amount of the VEGF antagonist. The formulation can also comprise one or more pharmaceutically acceptable carriers, buffers, tonicity agents, stabilizers, and/or excipients. An example of a pharmaceutically acceptable liquid formulation comprises a VEGF antagonist in a pharmaceutically effective amount, a buffer, an organic co-solvent such as polysorbate, a tonicity agent such as NaCl, and optionally, a stabilizer such as sucrose or trehalose.

Stability is determined in a number of ways at specified time points, including determination of pH, visual inspection of color and appearance, determination of total protein content by methods known in the art, e.g., UV spectroscopy, and purity is determined by, for example, SDS-PAGE, size-exclusion HPLC, bioassay determination of activity, isoelectric focusing, and isoaspartate quantification. In one example of a bioassay useful for determining VEGF antagonist activity, a BAF/3 VEGFR1/EPOR cell line is used to determine VEGF165 binding by the VEGF antagonist of the invention.

Liquid formulations can be stored in an oxygen-deprived environment. Oxygen-deprived environments can be gener-

ated by storing the formulations under an inert gas such as, for example, nitrogen or argon. Liquid formulations are preferably stored at about 5° C.

Ophthalmic Lyophilized Formulations

In one aspect of the invention, an ophthalmically acceptable formulation comprising a VEGF antagonist is provided, wherein the formulation is a lyophilizable formulation. Lyophilizable formulations can be reconstituted into solutions, suspensions, emulsions, or any other suitable form for administration or use. Lyophilizable formulations are typically first prepared as liquids, then frozen and lyophilized. The total liquid volume before lyophilization can be less, equal to, or more than, the final reconstituted volume of the lyophilized formulation. The lyophilization process is well known to those of ordinary skill in the art, and typically includes sublimation of water from a frozen formulation under controlled conditions.

Lyophilized formulations can be stored at a wide range of temperatures. Lyophilized formulations may be stored below 25° C., for example, refrigerated at 2-8° C., or at room temperature (e.g., approximately 25° C.). Preferably, lyophilized formulations are stored below about 25° C., more preferably, at about 4-20° C.; below about 4° C.; below about -20° C.; about -40° C.; about -70° C., or about -80° C. Stability of the lyophilized formulation may be determined in a number of ways known to the art, for example, by visual appearance of the cake and/or by moisture content.

Lyophilized formulations are typically reconstituted for use by addition of an aqueous solution to dissolve the lyophilized formulation. A wide variety of aqueous solutions can be used to reconstitute a lyophilized formulation. Preferably, lyophilized formulations are reconstituted using water. Lyophilized formulations are preferably reconstituted with a solution consisting essentially of water (e.g., USP WFI, or water for injection) or bacteriostatic water (e.g., USP WFI with 0.9% benzyl alcohol). However, solutions comprising buffers and/or excipients and/or one or more pharmaceutically acceptable carriers can also be used.

Freeze-dried or lyophilized formulations are typically prepared from liquids, that is, from solutions, suspensions, emulsions, and the like. Thus, the liquid that is to undergo freeze-drying or lyophilization preferably comprises all components desired in a final reconstituted liquid formulation. As a result, when reconstituted, the freeze-dried or lyophilized formulation will render a desired liquid formulation upon reconstitution.

EXAMPLES

Before the present methods are described, it is to be understood that this invention is not limited to particular methods, and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only to the appended claims.

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus for example, a reference to “a method” includes one or more methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this

invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference in their entirety.

Example 1. Stability of 50 mg/ml VEGF Trap Liquid Formulation Stored at 5° C. in 3 ml Glass Vials

An ophthalmic liquid formulation containing 50 mg/ml VEGF Trap (SEQ ID NO:4), 10 mM phosphate, 50 mM NaCl, 0.1% polysorbate 20, 5% sucrose, and pH 6.25, was stored at 5° C. in 3 ml glass vials and samples tested at 3, 6, 9, 12, 18 and 24 months. Stability was determined by SE-HPLC. The results are shown in Table 1. Turbidity was measured at OD₄₀₅ nm; and percent recovered protein and purity by size exclusion HPLC.

TABLE 1

Stability of 50 mg/ml VEGF Trap Protein (VGFT-SS065)					
Months	Visual Appearance	Turbidity (OD ₄₀₅ nm)	pH	% VEGF Trap Recovered	% VEGF Trap Native Configuration
0	Pass	0.00	6.2	100	98.8
3	Pass	0.00	6.2	101	98.7
6	Pass	0.01	6.3	100	98.3
9	Pass	0.01	6.3	101	98.3
12	Pass	0.01	6.3	104	98.4
18	Pass	0.01	6.3	96	98.1
24	Pass	0.01	6.3	105	98.1

Example 2. Stability of 50 mg/ml VEGF Trap Liquid Formulation Stored at 5° C. in 3 ml Glass Vials

A liquid formulation containing 50 mg/ml VEGF Trap (SEQ ID NO:4), 10 mM phosphate, 50 mM NaCl, 3% polyethylene glycol 3350, 5% sucrose, and pH 6.25, was stored at 5° C. in 3 ml glass vials and samples tested at 3, 6, 9, 12, 18 and 24 months. Stability results are shown in Table 2. Turbidity, percent recovered protein and purity was determined as described above.

TABLE 2

Stability of 50 mg/ml VEGF Trap Protein (VGFT-SS065)					
Months	Visual Appearance	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Configuration
0	Pass	0.00	6.2	100	98.9
3	Pass	0.00	6.1	104	98.5
6	Pass	0.01	6.3	99	98.3
9	Pass	0.00	6.3	102	97.6
12	Pass	0.01	6.3	103	98.0
18	Pass	0.00	6.3	113	97.7
24	Pass	0.00	6.2	106	97.6

Example 3. Stability of 40 mg/ml VEGF Trap Liquid Formulation Stored at 5° C. in 3 ml Glass Vials

A liquid formulation containing 40 mg/ml VEGF Trap (SEQ ID NO:4), 10 mM phosphate, 40 mM NaCl, 0.03%

9

polysorbate 20, 5% sucrose, and pH 6.3, was stored at 5° C. in 3 ml glass vials and samples tested at 0.5, 1, 2, 3, and 4 months. Stability results are shown in Table 3. Turbidity, percent recovered protein and purity was determined as described above.

TABLE 3

Stability of 40 mg/ml VEGF Trap Protein (VGFT-SS207)					
Months	Visual Appearance	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Configuration
0	Pass	0.00	6.3	100	99.5
0.5	Pass	0.00	6.3	99	99.4
1	Pass	0.00	6.2	98	99.5
2	Pass	0.00	6.2	95	99.2
3	Pass	0.01	6.4		
4	Pass	0.01	6.3		

Example 4. Stability of 40 mg/ml VEGF Trap Liquid Formulation Stored at 5° C. in Pre-Filled Glass Syringe

A liquid formulation containing 40 mg/ml VEGF trap (SEQ ID NO:4), 10 mM phosphate, 40 mM NaCl, 0.03% polysorbate 20, 5% sucrose, and pH 6.3, was stored at 5° C. in 1 ml prefilled luer glass syringe with 4023/50 FluroTec coated plunger and samples tested at 0.5, 1, 2, 3, and 4 months. Stability results are shown in Table 4. Turbidity, percent recovered protein and purity was determined as described above.

TABLE 4

Stability of 40 mg/ml VEGF Trap Protein (VGFT-SS207)					
Months	Visual Appearance	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Configuration
0	Pass	0.00	6.3	100	99.4
0.5	Pass	0.00	6.3	100	99.3
1	Pass	0.00	6.3	100	99.4
2	Pass	0.00	6.3	97	99.1
3	Pass	0.01	6.4		
4	Pass	0.01	6.3		

Example 5. Stability of 40 mg/ml VEGF Trap Liquid Formulation Stored at 5° C. in 3 ml Glass Vials

A liquid formulation containing 40 mg/ml VEGF trap (SEQ ID NO:4), 10 mM phosphate, 135 mM NaCl, 0.03% polysorbate 20, and pH 6.3, was stored at 5° C. in 3 ml glass vials and samples tested at 0.5, 1, 2, 3, and 4 months. Stability results are shown in Table 5. Turbidity, percent recovered protein and purity was determined as described above.

TABLE 5

Stability of 40 mg/ml VEGF Trap Protein (VGFT-SS203)					
Months	Visual Appearance	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Configuration
0	Pass	0.00	6.3	100	99.3
0.5	Pass	0.00	6.2	87	99.2

10

TABLE 5-continued

Stability of 40 mg/ml VEGF Trap Protein (VGFT-SS203)					
Months	Visual Appearance	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Configuration
1	Pass	0.00	6.2	88	99.1
2	Pass	0.00	6.3	103	99.2
3	Pass	0.00	6.3	88	99.0
4	Pass	0.00	6.2	85	98.9
5	Pass	0.00	6.3	84	99.0

Example 6. Stability of 40 mg/ml VEGF Trap Liquid Formulation Stored at 5° C. in 1 ml Pre-Filled Glass Syringe

A liquid formulation containing 40 mg/ml VEGF trap (SEQ ID NO:4), 10 mM phosphate, 135 mM NaCl, 0.03% polysorbate 20, and pH 6.3, was stored at 5° C. in 1 ml prefilled glass luer syringe with 4023/50 FluroTec coated plunger and samples tested at 0.5, 1, 2, 3, 4, and 5 months. Stability results are shown in Table 6. Turbidity, percent recovered protein and purity was determined as described above.

TABLE 6

Stability of 40 mg/ml VEGF Trap Protein (VGFT-SS203)					
Months	Visual Appearance	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Configuration
0	Pass	0.00	6.3	100	99.2
0.5	Pass	0.01	6.3	101	99.2
1	Pass	0.00	6.3	101	99.2
2	Pass	0.00	6.3	—	—
3	Pass	0.01	6.3	102	99.1
4	Pass	0.01	6.3	103	98.8
5	Pass	0.00	6.3	99	98.9

Example 7. Stability of Lyophilized 20 mg/ml VEGF Trap Formulation Stored at 5° C. in 3 ml Glass Vials and Reconstituted to 40 mg/ml

0.8 ml of a liquid formulation containing 20 mg/ml VEGF trap (SEQ ID NO:4), 5 mM phosphate, 20 mM NaCl, 0.015% polysorbate 20, 2.5% sucrose, and pH 6.3, were lyophilized in 3 ml glass vials. Samples were stored at 5° C. and tested at 1, and 2 months. VEGF trap was reconstituted to a final concentration of 40 mg/ml VEGF Trap (final volume of 0.4 ml). Stability results are shown in Table 7 (t=time in months; *=visual appearance; **=reconstitution time). Turbidity, percent recovered protein and purity was determined as described above.

TABLE 7

Stability of Lyophilized 20 mg/ml VEGF Trap Protein (VGFT-SS216)							
t	Vis. App.*	Recon. Time** (min)	Vis. App.* Reconst'd Liquid	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Config.
0	Pass	0.6	Pass	0.00	6.3	100	99.5
1	Pass	0.6	Pass	0.01	6.3	106	99.4
2	Pass	0.4	Pass	0.01	6.2	103	99.3

11

Example 8. Stability of Lyophilized 20 mg/ml
VEGF Trap Formulation Stored at 5° C. in 3 ml
Glass Vials

0.8 ml of a liquid formulation containing 20 mg/ml VEGF trap (SEQ ID NO:4), 5 mM phosphate, 67.5 mM NaCl, 0.015% polysorbate 20, and pH 6.3, were lyophilized in 3 ml glass vials. Samples were stored at 5° C. and tested at 1, 2, and 3 months. VEGF trap was reconstituted to a final concentration of 40 mg/ml VEGF trap (final volume of 0.4 ml). Stability results are shown in Table 8 (t=time in months; *=visual appearance; **=reconstitution time).

12

TABLE 8

Stability of Lyophilized 20 mg/ml VEGF Trap Protein (VGFT-SS216)							
t	Vis. App.*	Recon. Time** (min)	Vis. App. Reconst'd Liquid	Turbidity	pH	% VEGF Trap Recovered	% VEGF Trap Native Config.
0	Pass	0.7	Pass	0.00	6.3	100	99.0
1	Pass	0.7	Pass	0.01	6.2	105	98.9
2	Pass	0.4	Pass	0.01	6.2	103	98.9

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1

<211> LENGTH: 1453

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 1

```

aagcttgggc tgcaggtcga tcgactctag aggatcgatc ccgggcgag ctcgaattcg      60
caaccacccat ggtcagctac tgggacaccg gggtcctgct gtgcgcgctg ctcagctgtc      120
tgcttctcac aggatctagt tccggaggtg gacctttcgt agagatgtac agtgaatatc      180
ccgaaattat acacatgact gaaggaaggg agctcgatc tccctgccgg gttacgtcac      240
ctaacatcac tgttacttta aaaaagtttc cacttgacac tttgatccct gatggaaaac      300
gcataatctg ggacagtaga aagggcttca tcatatcaaa tgcaacgtac aaagaaatag      360
ggcttctgac ctgtgaagca acagtcaatg ggcatattgta taagacaaac tatctcacac      420
atcgacaaac caatacaatc atagatgtgg ttctgagtcg gtctcatgga attgaactat      480
ctgttgggaga aaagcttgct ttaaattgta cagcaagaac tgaactaaat gtggggattg      540
acttcaactg ggaataccct tcttcgaagc atcagcataa gaaacttgta aaccgagacc      600
taaaaaccca gtctgggagt gagatgaaga aatttttgag caccttaact atagatgggtg      660
taaccgggag tgaccaagga ttgtacacct gtgcagcatc cagtgggctg atgaccaaga      720
agaacagcac atttgtcagg gtccatgaaa agggcccggg cgacaaaact cacacatgcc      780
caccgtgccg agcacctgaa ctctggggg gaccgtcagt cttcctcttc ccccaaaac      840
ccaaggacac cctcatgate tcccggaacc ctgaggtcac atgctgggtg gtggacgtga      900
gccacgaaga ccctgaggtc aagtccaact ggtacgtgga cggcgtggag gtgcataatg      960
ccaagacaaa gcgcggggag gagcagtaca acagcacgta ccgtgtggto agcgtcctca      1020
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggto tccaacaaag      1080
ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc cgagaaccac      1140
aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggto agcctgacct      1200
gcctggtcaa aggtctctat cccagcgaca tcgcctgga gtgggagagc aatgggcagc      1260
cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc ttcttcctct      1320
atagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg      1380
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg tctccgggta      1440
aatgagcggc cgc                                         1453

```

-continued

```

<210> SEQ ID NO 2
<211> LENGTH: 458
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 2

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
1          5          10          15

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu
20          25          30

Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu
35          40          45

Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu
50          55          60

Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile
65          70          75          80

Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu
85          90          95

Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys
100         105         110

Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Val
115         120         125

Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu Lys Leu Val
130         135         140

Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile Asp Phe Asn
145         150         155         160

Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu Val Asn Arg
165         170         175

Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe Leu Ser Thr
180         185         190

Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu Tyr Thr Cys
195         200         205

Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr Phe Val Arg
210         215         220

Val His Glu Lys Gly Pro Gly Asp Lys Thr His Thr Cys Pro Pro Cys
225         230         235         240

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
245         250         255

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
260         265         270

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
275         280         285

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
290         295         300

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
305         310         315         320

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
325         330         335

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
340         345         350

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
355         360         365

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

```

-continued

370	375	380	
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn			
385	390	395	400
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe			
	405	410	415
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn			
	420	425	430
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr			
	435	440	445
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys			
	450	455	

<210> SEQ ID NO 3
 <211> LENGTH: 1377
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 3

atggtcagct actgggacac cggggctctg ctgtgcgcgc tgctcagctg tctgcttctc	60
acaggatcta gttccggaag tgataccggt agacctttcg tagagatgta cagtgaatc	120
cccgaaatta tacacatgac tgaaggaagg gagctcgtca ttcctgccc ggttacgtca	180
cctaacaatca ctgttacttt aaaaaagttt ccacttgaca ctttgatccc tgatggaaaa	240
cgcataatct gggacagtag aaagggtctc atcatatcaa atgcaacgta caaagaaata	300
gggcttctga cctgtgaagc aacagtcaat gggcatttgt ataagacaaa ctatctcaca	360
catcgacaaa ccaatacaat catagatgtg gttctgagtc cgtctcatgg aattgaacta	420
tctgttgagg aaaagcttgt cttaaattgt acagcaagaa ctgaactaaa tgtggggatt	480
gacttcaact ggggaataccc ttcttgaag catcagcata agaaacttgt aaaccgagac	540
ctaaaaacc agtctgggag tgagatgaag aaatttttga gcaccttaac tatagatggt	600
gtaaccgga gtgaccaagg attgtacacc tgtgcagcat ccagtgggct gatgaccaag	660
aagaacagca catttgtcag ggtccatgaa aaggacaaaa ctcacacatg cccaccgtgc	720
ccagcacctg aactcctggg gggaccgtca gtcttctct tcccccaaa acccaaggac	780
accctcatga tctcccgac cctgaggtc acatgcgtgg tggaggagct gagccacgaa	840
gacctgagg tcaagttaa ctggtagctg gacggcgtgg aggtgcataa tgccaagaca	900
aagccgcggg aggagcagta caacagcagc taccgtgtgg tcagcgtcct caccgtctg	960
caccaggact ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca	1020
gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac	1080
accctgcccc catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc	1140
aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac	1200
aactacaaga ccagcctcc cgtgctggac tccgacggct ccttcttct ctacagcaag	1260
ctcaccgtgg acaagagcag gtggcagcag gggaaactct tctcatgctc cgtgatgcat	1320
gaggctctgc acaaccacta cagcagaag agcctctccc tgtctccggg taaatga	1377

<210> SEQ ID NO 4
 <211> LENGTH: 458
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 4

```

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
 1          5          10          15

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Asp Thr Gly Arg Pro
 20          25          30

Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu
 35          40          45

Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr
 50          55          60

Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys
 65          70          75          80

Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr
 85          90          95

Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His
 100         105         110

Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile
 115         120         125

Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu
 130         135         140

Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile
 145         150         155         160

Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu
 165         170         175

Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe
 180         185         190

Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu
 195         200         205

Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr
 210         215         220

Phe Val Arg Val His Glu Lys Asp Lys Thr His Thr Cys Pro Pro Cys
 225         230         235         240

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 245         250         255

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 260         265         270

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 275         280         285

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 290         295         300

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 305         310         315         320

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 325         330         335

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 340         345         350

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 355         360         365

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 370         375         380

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 385         390         395         400

```

-continued

Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe
				405					410					415	
Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn
			420					425					430		
Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr
		435					440					445			
Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys						
	450					455									

We claim:

1. A glass vial comprising an ophthalmic formulation suitable for intravitreal administration comprising:
 - a vascular endothelial growth factor (VEGF) antagonist fusion protein,
 - an organic co-solvent,
 - a buffer, and
 - a stabilizing agent;
 wherein said VEGF antagonist fusion protein is glycosylated and comprises an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor that is human Flt1 and Ig domain 3 of a second VEGF receptor selected from the group consisting of human Flk1 and human Flt4, and a multimerizing component; and
 - wherein at least 98% of said VEGF antagonist fusion protein is present in native conformation following storage at 5° C. for two months as measured by size exclusion chromatography.
2. The glass vial of claim 1, wherein the concentration of said VEGF antagonist fusion protein is 40 mg/ml, and wherein said organic co-solvent comprises polysorbate.
3. The glass vial of claim 2, wherein said organic co-solvent comprises 0.01% to 3% polysorbate.
4. The glass vial of claim 2, wherein said organic co-solvent comprises about 0.03% to about 0.1% polysorbate.
5. The glass vial of claim 2, wherein said organic co-solvent comprises 0.01% to 3% polysorbate.
6. The glass vial of claim 5, wherein said buffer comprises a phosphate buffer.
7. The glass vial of claim 5, wherein said buffer comprises 5-25 mM buffer.
8. The glass vial of claim 5, wherein said buffer comprises a pH between about 5.8-7.0.
9. The glass vial of claim 5, wherein said buffer comprises a pH about 6.2-6.3.
10. The glass vial of claim 5, wherein said stabilizing agent comprises a sugar.
11. The glass vial of claim 10, wherein said sugar is selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol.
12. The glass vial of claim 5, wherein said stabilizing agent comprises 1.0-7.5% of sucrose.
13. The glass vial of claim 5, wherein said formulation further comprises a tonicity agent.
14. The glass vial of claim 5, wherein said VEGF antagonist fusion protein is glycosylated at asparagine residues corresponding to asparagine residues 62, 94, 149, 222 and 308 of SEQ ID NO: 4.
15. The glass vial of claim 5, wherein said formulation is capable of providing a turbidity of 0.01 or lower at OD₄₀₅ after 2 month storage at 5° C.
16. The glass vial of claim 5, wherein at least 99% of said VEGF antagonist fusion protein is present in native conformation after 2 month storage at 5° C. as measured by size exclusion chromatography.
17. The glass vial of claim 5, wherein at least 98% of said VEGF antagonist fusion protein is present in native conformation following storage at 5° C. for 24 months as measured by size exclusion chromatography.
18. The glass vial of claim 5, wherein said formulation does not contain phosphate.
19. The glass vial of claim 5, wherein said formulation does not contain trehalose.
20. The glass vial of claim 5, wherein said stabilizing agent comprises 1.0-10% of sucrose.
21. The glass vial of claim 20, wherein said formulation further comprises a tonicity agent.
22. The glass vial of claim 20, wherein said VEGF antagonist fusion protein is glycosylated at asparagine residues corresponding to asparagine residues 62, 94, 149, 222 and 308 of SEQ ID NO: 4.
23. The glass vial of claim 20, wherein said formulation is capable of providing a turbidity of 0.01 or lower at OD₄₀₅ after 2 month storage at 5° C.
24. The glass vial of claim 20, wherein at least 99% of said VEGF antagonist fusion protein is present in native conformation after 2 month storage at 5° C. as measured by size exclusion chromatography.
25. The glass vial of claim 20, wherein at least 98% of said VEGF antagonist fusion protein is present in native conformation following storage at 5° C. for 24 months as measured by size exclusion chromatography.
26. The glass vial of claim 1, wherein said stabilizing agent comprises sucrose.
27. The glass vial of claim 26, wherein said stabilizing agent comprises 1.0-10% of sucrose.
28. The glass vial of claim 26, wherein the organic co-solvent is polysorbate.
29. The glass vial of claim 28, wherein said Ig domain 3 of human VEGF receptor 2 comprises amino acids 131-230 of SEQ ID NO:4.
30. The glass vial of claim 29, wherein said formulation further comprises a tonicity agent.
31. The glass vial of claim 30, wherein said tonicity agent comprises sodium chloride.
32. The glass vial of claim 28, wherein said formulation comprises 10 mg/mL VEGF antagonist fusion protein.
33. The glass vial of claim 28, wherein said formulation does not contain phosphate.
34. A pre-filled syringe comprising an ophthalmic formulation suitable for intravitreal administration comprising:
 - a vascular endothelial growth factor (VEGF) antagonist fusion protein,

21

an organic co-solvent,
a buffer, and
a stabilizing agent;

wherein said VEGF antagonist fusion protein is glycosylated and comprises an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor that is human Flt1 and Ig domain 3 of a second VEGF receptor selected from the group consisting of human Flk1 and human Flt4, and a multimerizing component; and
wherein at least 98% of said VEGF antagonist fusion protein is present in native conformation following storage at 5° C. for two months as measured by size exclusion chromatography.

35. The pre-filled syringe of claim 34, wherein the concentration of said VEGF antagonist fusion protein is 40 mg/ml, and wherein said organic co-solvent comprises polysorbate.

36. The pre-filled syringe of claim 35, wherein said organic co-solvent comprises 0.01% to 3% polysorbate.

37. The pre-filled syringe of claim 35, wherein said organic co-solvent comprises about 0.03% to about 0.1% polysorbate 20.

38. The pre-filled syringe of claim 35, wherein said organic co-solvent comprises 0.01% to 3% polysorbate 20.

39. The pre-filled syringe of claim 38, wherein said buffer comprises 5-25 mM buffer.

40. The pre-filled syringe of claim 38, wherein said buffer comprises a pH between about 5.8-7.0.

41. The pre-filled syringe of claim 38, wherein said buffer comprises a pH about 6.2-6.3.

42. The pre-filled syringe of claim 38, wherein said buffer comprises a phosphate buffer.

43. The pre-filled syringe of claim 38, wherein said stabilizing agent comprises a sugar.

44. The pre-filled syringe of claim 43, wherein said sugar is selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol.

45. The pre-filled syringe of claim 38, wherein said stabilizing agent comprises 1.0-10% of sucrose.

46. The pre-filled syringe of claim 45, wherein said formulation further comprises a tonicity agent.

47. The pre-filled syringe of claim 45, wherein said VEGF antagonist fusion protein is glycosylated at asparagine residues corresponding to asparagine residues 62, 94, 149, 222 and 308 of SEQ ID NO: 4.

48. The pre-filled syringe of claim 45, wherein said formulation is capable of providing a turbidity of 0.01 or lower at OD₄₀₅ after 2 month storage at 5° C.

49. The pre-filled syringe of claim 45, wherein at least 99% of said VEGF antagonist fusion protein is present in

22

native conformation after 2 month storage at 5° C. as measured by size exclusion chromatography.

50. The pre-filled syringe of claim 45, wherein at least 98% of said VEGF antagonist fusion protein is present in native conformation following storage at 5° C. for 24 months as measured by size exclusion chromatography.

51. The pre-filled syringe of claim 38, wherein said stabilizing agent comprises 1.0-7.5% of sucrose.

52. The pre-filled syringe of claim 38, wherein said formulation further comprises a tonicity agent.

53. The pre-filled syringe of claim 38, wherein said VEGF antagonist fusion protein is glycosylated at asparagine residues corresponding to asparagine residues 62, 94, 149, 222 and 308 of SEQ ID NO: 4.

54. The pre-filled syringe of claim 38, wherein said formulation is capable of providing a turbidity of 0.01 or lower at OD₄₀₅ after 2 month storage at 5° C.

55. The pre-filled syringe of claim 38, wherein at least 99% of said VEGF antagonist fusion protein is present in native conformation after 2 month storage at 5° C. as measured by size exclusion chromatography.

56. The pre-filled syringe of claim 38, wherein at least 98% of said VEGF antagonist fusion protein is present in native conformation following storage at 5° C. for 24 months as measured by size exclusion chromatography.

57. The pre-filled syringe of claim 38, wherein said formulation does not contain phosphate.

58. The pre-filled syringe of claim 38, wherein said formulation does not contain trehalose.

59. The pre-filled syringe of claim 34, wherein said stabilizing agent comprises sucrose.

60. The pre-filled syringe of claim 59, wherein said stabilizing agent comprises 1.0-10% of sucrose.

61. The pre-filled syringe of claim 59, wherein the organic co-solvent is polysorbate 20.

62. The pre-filled syringe of claim 61, wherein said Ig domain 3 of human VEGF receptor 2 comprises amino acids 131-230 of SEQ ID NO:4.

63. The pre-filled syringe of claim 62, wherein said formulation further comprises a tonicity agent.

64. The pre-filled syringe of claim 63, wherein said tonicity agent comprises sodium chloride.

65. The pre-filled syringe of claim 61, wherein said formulation comprises 10 mg/mL VEGF antagonist fusion protein.

66. The pre-filled syringe of claim 61, wherein said formulation does not contain phosphate.

* * * * *